Drug
NP 101
NP 101: highest development phase Phase 2/3, developed by Novatek Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Novatek Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| NP-101 NCT07935928 | Phase 2/3 | Gastroenteropancreatic Neuroendocrine Tumors |
Latest
No recent events.
Follow NP 101 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.